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Summary We have partially purified an archaebacterial protein of 84kD which shares common epitopes
with the human c-myc protein as shown by its cross-reactivity with a commercialized anti-human c-myc
antiserum.
An antiserum raised against the 84kD protein recognizes a 60kD protein from HL-60 nuclei. This protein
is also recognized by the anti-human c-myc antiserum.
Using this archaebacterial protein as antigen for Western blot analysis, we found that the human c-myc
oncogene product could be immunogenic and that it is possible, in some spontaneously occurring human
tumours, to detect antibodies against the c-myc gene product in the serum of cancer patients.
It has been shown that cancer patients may develop a cell-
mediated and humoral response to various associated anti-
gens. This recognition process is difficult to identify because
the responses expressed by both patients and healthy indivi-
duals are not specific. The target structures for immune
recognition that have been characterized do not show real
tumour specificity in most experiments, but the presence of
antibodies during malignancies may be clinically important
for prognosis and follow up (Mastrangelo et al., 1984). In
contrast to recent progress in the cellular immunology of
cancer, the role of humoral immunity in oncogenesis remains
poorly understood.
'Serum enhancement' and 'blocking antibody' theories
suggest that B cell activation and antibody production could
promote tumour growth (Smith & Landy, 1970). On the
other hand, numerous studies deal with the fact that specific
antibodies can inhibit tumour cell growth in vitro or in vivo.
It has been shown that the level of circulating antitumour
antibodies may be modulated by tumour treatment. The fact
that antibodies may be effective in preventing the develop-
ment of metastasis rather than blocking the growth of the
primary tumour has also stressed the positive aspects of
humoral antitumour immunity (Seto et al., 1983; Witz, 1977;
Vaage & Agarwal, 1974). Chemically induced tumours are
often immunogenic: the host responds specifically in vivo to
the tumour by generating a state of concomitant antitumour
immunity (North, 1985).
Among spontaneously occurring human tumours, the
specific immune recognition of antigenic tumour cells may be
restricted to virally induced tumour and in particular to
those associated with DNA viruses (Klein & Klein, 1985).
Although several tumour antigens have been claimed to
be specific, and analysed for their role in immunological
responses in tumour-bearing host (Sulitzeanu, 1985), the
immunogenicity of cellular oncogene products has not yet
been reported. Among the latter is the myc family of onco-
genes, the expression of which has been demonstrated in
many tumours and cancer cell lines (Slamon et al., 1984;
Sikora et al., 1985).
We have previously described the presence in the archae-
bacterium Halobacterium halobium genome of DNA frag-
ments which hybridize with a v-myc probe. A comparison of
appropriate H. halobium genomic clones with the v-myc gene
showed regions of significant homology (Ben-Mahrez et al.,
1988a). Moreover, hybridization experiments showed that
these bacteria possess two RNA molecules homologous to
the v-myc oncogene (Ben-Mahrez et al., 1988b).
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Experiments on the immunogenicity of the myc oncogene
product are restricted by the fact that the purified protein is
not available in quantity. We report here a solution to the
problem of protein limitation, using the properties of a
protein from H. halobium which reacts with an anti-human
c-myc antiserum. Preliminary experiments suggest that the
myc oncogene product could be immunogenic during the
transformation process and that it is possible to detect
antibodies against the myc protein in the serum of some
cancer patients.
Materials and methods
Strain and culture
H. halobium CCM2090 was cultured in classical halophilic
medium as described previously (Sehgal & Gibbons, 1960) to
an absorbance of 1.4 at 600nm.
Eukaryotic cell cultures
HL-60 cells were cultured as previously described (Grosso &
Pitot, 1984). MCF-7 and OD262 cells were cultured in 10%
foetal calf serum in MEM medium, at 37°C in 5% CO2
(Kozbor & Croce, 1984).
Antibodies
Polyclonal antibodies raised against a human c-myc synthetic
peptide were purchased from Oncor Inc. USA, anti-IgG
antiserum linked to peroxidase was from Miles Scientific.
Cancer patients and healthy individuals sera
Blood samples from cancer patients and healthy individuals
were obtained with informed consent. Serums were stored at
-20°C prior to test.
Human c-myc synthetic peptides
Two different peptides were chemically synthesized by Toray
Research Center (Japan). The E peptide sequence is: His-
Gln-His-Asn-Tyr-Ala-Ala-Pro-Pro-Ser-Thr-Arg-Lys (amino
acids 305 to 318 of the human c-myc protein). The F peptide
corresponds to the carboxy-terminal amino acid sequence of
the human c-myc protein (Colby et al., 1983): Arg-Lys-Arg-
Arg-Glu-Gln-Leu-Lys-His-Lys-Leu-Glu-Gln-Leu-Arg-Asn-
Ser-Cys-Ala.
Preparation of DNA free extracts from H. halobium
Twenty-five g of frozen H. Halobium cells were resuspended
in 25ml of buffer containing 25mM HEPES pH 7.5, 3M KCI,
1 mM EDTA, 1 mm phenylmethylsulfonyl fluoride and 2mM
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dithiothreitol and disrupted using a Potter homogenizer at
4°C. After centrifugation (100,OOOg, 60min) at 4°C,
soluble and fast sedimenting materials were separated. The
fast sedimenting materials containing cell envelopes and most
of the nucleic acid were sonicated.
After centrifugation (5,000g, 10min), the upper phase was
treated for 1 h at 37°C with DNaseI (10pgml-1 in O.O1M
MgCl2) and tested by Western blot analysis for the presence
of human c-myc like protein.
Purification of the 84kD protein
The 84kD protein was assayed by Western blot analysis
using the anti-c-myc antiserum. The extract treated by
DNaseI and containing the c-myc like protein (1,000mg of
protein) was passed through a column of DEAE-cellulose
(DE52) (3 x 15cm) previously equilibrated with 20mM
sodium phosphate pH7.3, 100mm KCI and 10% (v/v)
glycerol. Under these conditions, the 84kD protein was
found in the non-adsorbed and washed fractions which were
then chromatographed on a column of hydroxylapatite
(3 x 1Ocm) previously equilibrated with 1Omm sodium phos-
phate pH 6.8, 100mm KCI and 10% (v/v) glycerol. After
washing, the 84kD protein was eluted with 300 ml of 0.3M
Na2 HPO4.
Preparation ofpurified HL-60 nuclei
HL-60 nuclei were purified according to the method of
Lebkowski & Laemmli (1982).
Western blot analysis
The H. halobium or eukaryotic cell proteins were precipitated
by trichloroacetic acid (6%) and the pellet was resuspended,
after washing with acetone, in 10mm sodium phosphate
pH 7.0, 1% sodium dodecyl sulfate (SDS) and 1% 2-
mercaptoethanol and heated at 100°C for 5min. After
electrophoresis on SDS-10% polyacrylamide gel, the proteins
were electrophoretically transferred onto Millipore nitrocellu-
lose at 60 volts for 2h 30min at 4°C. The transfer buffer
consisted of 25mm Tris-HCl pH8.5, 192mm glycine and
20% (v/v) methanol. After transfer, the blot was washed for
2h in buffer X (50mm Tris-HCl pH 7.5, 200mm NaCl, 0.1%
Tween 20 and 0.25% gelatin) and incubated overnight at
4°C in buffer X containing the antibodies. Then, the blot
was rinsed 3 times for 5min in buffer X and incubated for
2h at 4°C with anti-IgG antiserum linked to peroxidase in
buffer X.
After 3 rinses in buffer X without gelatin, the blot was
revealed by incubating for 45min in buffer containing 15mg
4-chloro-1-naphthol (Sigma), 5ml methanol, 25ml of buffer
(50mM Tris-HCl pH7.5 and 200mm NaCl) and 20pl H202
(9%).
Preparation of an antiserum directed against the 84kD
protein
A rabbit was immunized with 100 ug protein in Freund's
complete adjuvant by injection at multiple s.c. sites. A
booster immunization, containing 100 g protein in Freund's
incomplete adjuvant was administered after 3 weeks. Bleed-
ings were performed 15 days after injection.
Results
C-myc related protein of H. halobium
Figure 1 demonstrates that a protein of 84kD present in fast
sedimenting materials cross reacted with the anti-human c-
myc antiserum. Such a cross-reacting protein was not seen in
the soluble fraction.
We have examined whether this antiserum specifically
recognizes the human c-myc protein. Using extracts of a
human promyelocytic leukaemia cell line, HL-60, which is
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Figure 1 Identification of an 84kD protein related to the
human c-myc gene product: 100 g protein from soluble fraction
(a) or the sedimenting materials (b) were subjected to Western
blot analysis using anti-human c-myc antiserum (1/30 dilution) as
described in Materials and methods. The 84kD protein is indi-
cated by a triangle.
known to express c-myc (Grosso & Pitot, 1984), it was found
that the anti-human c-myc reacted with two proteins of
60kD and 42kD (Figure 2a).
The presence of dimethylsulfoxide in HL-60 cell cultures is
known to inhibit the synthesis of the c-myc protein (Grosso
& Pitot, 1984). The disappearance of both the 60kD and
42kD proteins was observed after 48h dimethylsulfoxide
treatment (Figure 2b). It has already been reported that a 47
or 49kD protein has a similar epitope to the c-myc protein
and is subject to dimethylsulfoxide treatment (Faletto et al.,
1985; Persson et al., 1984a). As the c-myc product is a
nuclear protein, but the 47kD protein is not (Persson &
Leder, 1984b), HL-60 nuclei were purified, extracted and
tested with the anti-human c-myc antiserum. Only a peptide
of 60kD was detected by Western blot analysis (Figure 3c).
In order to confirm the identity between the 60kD protein
and the c-myc protein, two other human cell lines were
examined, a breast carcinoma cell line MCF-7 which is
negative (Kozbor & Croce, 1984) and an ovary carcinoma
cell line OD262 which is positive, for c-myc expression.
Figure 4 demonstrates that the 60kD protein was detected
both in HL-60 and OD262 but not in MCF-7. From these
results it was concluded that the 60kD protein recognized by
the antiserum (Oncor Inc.) is the human c-myc gene product.
Polyclonal antiserum against the 84kD protein
In order to show further similarities in epitopes between the
84kD protein of H. halobium and the c-myc protein, a
polyclonal antibody against the 84kD protein was prepared.
For this purpose the halophile protein was purified from
bacterial extracts (see Materials and methods). One major
protein band of 84kD was obtained when analysed onCIRCULATING ANTIBODIES AGAINST c-myc 531
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Figure 2 HL-60 cell protein pattern recognized by anti-human
c-myc antiserum using Western blot analysis: (a) 60,ug dimethyl-
sulfoxide treated HL-60 proteins; (b) 60ug HL-60 proteins. The
human c-myc protein is indicated by a triangle.
K
68-
60-
45-
25-
Figure 3 Western blot analysis of dimethylsulfoxide treated and
untreated HL-60 nuclei: HL-60 was cultivated with (a) or
without (b,c) dimethylsulfoxide (1.25%) for 48h: (a, b) anti-
84kD protein antiserum (1/100 dilution); (c) anti-human c-myc
antiserum (1/30 dilution). The human c-myc protein is indicated
by a triangle.
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Figure 4 Protein patterns from various cell lines recognized by
anti-human c-myc antiserum: (a) 60pg dimethylsulfoxide treated
HL-60 proteins; (b) 60pg HL-60 proteins; (c) 60pg OD262
proteins; (d) 60jug MCF-7 proteins. The human c-myc protein is
indicated by a triangle.
polyacrylamide gel under denaturing conditions. A rabbit
antiserum was raised against this preparation.
We then examined whether the antiserum against the
84kD protein could recognize the c-myc protein by Western
blot analysis. Figure 3 demonstrates that a 60kD protein in
nuclear extracts of HL-60 was revealed by our antiserum in
almost the same way as the anti-c-myc antiserum, and that
the loss of the c-myc protein provoked by dimethylsulfoxide
treatment paralleled the absence of the 60kD band in
Western blot analysis.
Recognition of the 84kD protein by human sera
The 84kD protein preparation was transferred onto Milli-
pore nitrocellulose and used to screen for the presence of
antibodies against the protein in the sera of cancer patients
or healthy individuals. Among the 212 sera tested 21 recog-
nized the 84kD protein in this screening test. Some examples
are shown in Figure 5. In order to confirm the validity of
the test, Western blot analysis was carried out using extracts
of dimethylsulfoxide treated or untreated HL-60 cells.
Despite the complexity of bands due to the homologous
system, a band of 60kD with a positive patient was seen
only in extracts of non-differentiated HL-60 (Figure 6);
which indicated recognition of the c-myc protein by the
positive serum. The c-myc protein being found in nuclei, it
was determined whether the 60kD protein recognized by the
positive serum was present in nuclear extracts. Figure 7
clearly shows that the positive serum reacted with a nuclear
60kD protein.
None of the 41 sera screened contained antibodies to the
84kD protein. Positive sera were from patients with colo-
rectal cancer (4 out of 6), breast cancer (12 out of 125)
osteosarcoma (1 out of 2), cancers of unknown origin (3 out
of 3), ovarian cancer (1 out of 9) (Table I). Four sera from
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Figure 5 Screening of human sera: Samples from cancer
patients were tested by Western blot analysis using 15pg par-
tially purified (-5% of total protein) 84kD protein as antigen:
1,2,4, negative sera (1/20 dilution); 3,5 positive sera (1/20 dilu-
tion). The 84kD protein is indicated by a triangle.
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Figure 7 Western blot analysis of a positive serum using 15pg
dimethylsulfoxide treated HL-60 nuclear proteins (a) and 15pg
HL-60 nuclear proteins (b) as antigen: A positive serum was used
at 1/20 dilution. The human c-myc protein is indicated by a
triangle.
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Figure 6 Western blot analysis of human sera using 60pg HL-
60 proteins (A) and 60pg dimethylsulfoxide treated HL-60
proteins (B) as antigen: (a) anti-human c-myc antiserum (1/30
dilution); (b, c,d) negative sera (1/20 dilution); (e) positive serum
(1/20 dilution). The human c-myc protein is indicated by a
triangle.
Table I Classification of responses according to cancer type
Cancer type No. positive No. negative
Breast (adenocarcinoma) 12 113
Melanoma 0 5
Colon 4 2
ORL 0 3
Ovary 1 8
Hodgkin's 0 8
Liver 0 1
Osteosarcoma 1 1
Uterus 0 2
Teratocarcinoma 0 1
Neuroblastoma 0 2
Cancers of unknown origin 3 0
patients with autoimmune disease (lupus erythematous) did
not react with the 84kD protein.
Competition between the 84kD protein and synthetic c-myc
peptides
Further evidence that the positive sera contain antibodies
against epitopes of the c-myc protein was obtained when
positive sera were pre-incubated with either peptide E corre-
sponding to the amino acid sequence of the c-myc protein
(305-318) or the peptide F(421-439). Recognition of the
84kD protein by a positive serum was diminished after pre-
incubation with either of the two synthetic peptides (Figure
8A).
Interestingly, another positive serum reacted only with
peptide F and not with peptide E (Figure 8B).
These results demonstrate that the positive sera contain
antibodies against epitopes contained in the amino acid
sequences E and F of the c-myc protein.
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Figure 8 Competition between the 84kD protein and synth-tic
c-myc peptides: Positive sera (A and B) were pre-incubated at 1/
20 dilution with the peptide E (el,e2,e3) or the peptide F
(fl,f2,f3) in buffer X, for 4h at 40C and then tested by Western
blot analysis using partially purified 84 kD protein as described
in the legend of Figure 5. The peptides were used at 50Ingir
(e1,f1); 50ngml (e2,f2) and lugmll (e3f3) Test without
pre-incubation (1/20 dilution) (a,b).
Discussion
Archaebacteria possess several eukaryotic charactenistics
(Zillig et al., 1985). This observation has been supported by
immunological techniques which have shown that the RNA
polymerase or the alpha type DNA polymerase from archae-
bacteria share common epitopes with their eukaryotic
counterparts (Huet et al., 1983; Kohiyama et al. 1986). In
the same way we have identified an 84kD protein from H.
halobium having similar epitopes to the human c-myc protein
and developed a serological screening test to detect anti-
bodies against the c-myc product.
The human c-myc protein was identified in the present
paper as a nuclear protein from HL 60 cells of approxi-
mately 60 kD by Western blot analysis using a commercial
anti-human c-myc antiserum. However, in common with
other authors (Faletto et al. 1985; Persson et al.1984a) this
antiserum was found to recognize not only the c-myc protein
but also another peptide of 42kD. The latter protein disap-
pears more slowly than the c-myc gene product when HL-60
cells are treated with dimethylsulfoxide (Faletto et al., 1985).
In the absence of absolute specificity of the antiserum the
question was raised whether the 84kD protein recognized by
the c-myc antiserum was similar to the human 42kD protein
rather than to the human c-myc product. To answer the
question, polyclonal antibody against the 84kD protein was
prepared which recognizes the nuclear 60kD protein of HL-
60. It was concluded that the 84kD protein of H. halobium
has similar epitopes to the human c-myc protein. Our results
are consistent with the observed homologies between a part
of the genome of H. halobium and the v-myc oncogene (Ben-
Mahrez et al., 1988a).
Using the archaebacterial 84kD protein (Figure 5) or HL-
60 extracts (Figures 6 & 7) as antigen, it was found that 21
out of 212 cancer patient sera contained circulating anti-
bodies against the c-myc protein. The results obtained with
either of the two antigens (84 and 60kD proteins) were the
same. However, it is clear that the 84kD protein preparation
has two advantages over HL-60 extracts viz. the simplicity of
the response patterns and the relative ease of preparation of
the 84kD protein.
Besides, it was shown by competition experiments that the
positive sera reacted in a different manner with two peptides
corresponding to two regions of the c-myc protein, probably
indicating differences in the antibodies produced by the
patients.
Although we have not studied a large panel of various
cancer types statistically it appears that circulating antibodies
to c-myc are not restricted to a particular type of cancer but
are more likely to be present in patients with various types.
The fact that many sera do not react with the 84kD protein
may be due to the absence of antibodies cross-reacting with
the 84kD protein (independently of the fact that anti c-myc
antibodies may be present) or to an inhibitory effect of
idiotypic antibodies in these sera.
As the myc gene product is a nuclear protein (Persson &
Leder, 1984b), these antibodies could be classified among the
antibodies to nuclear antigens (ANA), which have been
clinically associated with numerous autoimmune diseases. In
some malignant diseases ANAs may be important for diag-
nosis (Tan, 1982; Klein et al., 1974). On the other hand, an
immunization process may occur when the c-myc product is
exposed to immunocompetent cells due to tumour lysis
provoked by a therapeutically induced or natural tumour
necrosis. This immunization could be more frequent when
the tumour is infiltrated by mononuclear cells, or when the
tumour is close to a lymphoid organ such as Peyer's patches
in colon tumours (Martin et al., 1986). Whether antibodies
to the human c-myc protein reflect an autoimmune process
or one induced by sensitisation during tumour necrotic or
inflammatory processes remains to be studied.
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